ASCO 2009: Significant Developments in Context

Publication Date	July 2009
Publisher	FirstWord
Product Type	Report
Pages	175
ISBN Number	not applicable
Product Code	FWD00002

Buy this product or for assistance call +44 20 7060 7474

PDF £595.00$990 | €666

FAX Order above formats by FAX

Summary

The recent ASCO meeting was attended by around 30,000 cancer researchers and physicians and over 4,000 abstracts covering a wide range of clinical trial results and related topics were presented. How do you make sense of it all and, more importantly, what were the developments that were really important?

This new FirstWord Dossier brings clarity and insight

FirstWord's new analysis of the latest ASCO meeting highlights and presents selected information on the significant announcements from the conference in an easy-to-use digest. FirstWord's team of experienced medical journalists were on-hand to critically review and report the latest developments and thinking and this information, augmented by pre- and post-conference data released by developers, is the basis of this detailed 175-page research dossier.

Just a taste of the content ...

Eli Lilly's announcement regarding latest research findings on Alimta (pemetrexed) in the treatment of advanced - other than predominantly squamous - non-small-cell lung cancer (NSCLC), was regarded by many as one of the highlights of the conference.

Significant announcements also came from:

Pfizer (PF-02341066) - NSCLC
Seattle Genetics (SGN-35) - Hodgkin lymphoma/anaplastic

large cell lymphoma

Roche (trastuzumab) - gastric cancer
Genentech/Roche/Immunomedics (trastuzumab-DM1) - breast cancer
AstraZeneca (gefitinib) - NSCLC
Cancer Research UK (gemcitabine/cisplatin combination)
biliary-tract cancer
Roche (erlotinib; erlotinib/bevacizumab) - NSCLC
Biovest International (BiovaxID) - follicular lymphoma

This research provides:

An easy and well-indexed reference to the latest developments by cancer type or treatment area.
Current thinking with the report focusing on developments at the conference, updated with the latest product information.
An objective and independent review free from commercial spin.
A cost-effective and time-saving appraisal giving you the insight you need with the minimum of effort.

Content

Executive Summary
Chemotherapy-Induced Conditions
- Aphios announces presentation of Phase II/III clinical trial data on Zindol for chemotherapy-induced nausea
- A.P. Pharma presents APF530 Phase III data
Brain Cancer
- Neurobiological Technologies' partner, Celtic Pharma, announces results of Xerecept Phase III clinical programme
- Update on CDX-110 (PF-04948568) Phase II brain cancer studies
- Phase II data presented for in patients with previously treated glioblastoma multiforme
- Study shows cilengitide increased overall survival in patients with glioblastoma
Head/Neck Cancer
- BioVex reports Phase I/II clinical trial results for the front line treatment of head and neck cancer with OncoVEX-CSF
- Tumour HPV status predicts survival in patients with oropharynx cancers
Neuroblastoma
- Novel Immunotherapy Improves Survival in Children with Neuroblastoma
Breast Cancer
- Cytokinetics presents clinical data relating to ispinesib in patients with metastatic breast cancer
- Concurrent use of tamoxifen, antidepressants associated with double risk of breast cancer relapse
- Data show use of certain antidepressants with tamoxifen increases risk of recurrent breast cancer
- Ixabepilone plus bevacizumab demonstrates encouraging activity relative to paclitaxel plus bevacizumab for metastatic breast cancer
- BSI-201 showed clinical benefit in 62 percent of patients with triple-negative metastatic breast cancer and significantly prolonged survival
- Peregrine Pharmaceuticals highlights promising early data from its three Phase II bavituximab cancer trials
- Peregrine Pharmaceuticals presents promising data from its Phase II bavituximab breast cancer trial
- Bevacizumab Added to First-Line Chemotherapy Improves Progression-Free Survival in Metastatic Breast Cancer
- Avastin plus commonly used chemotherapies improved progression-free survival in advanced breast cancer
- Monogram presents three studies describing HERmark's ability to select trastuzumab responders and non-responders
- CuraGen updates CR011-vcMMAE data
- Cognitive function better with letrozole than with tamoxifen in patients treated for breast cancer
- Study explores potential benefit of nab-paclitaxel in combination with bevacizumab for the first-line treatment of metastatic breast cancer
- Micromet presents update on a Phase Ib combination study of adecatumumab and docetaxel
- ImmunoGen announces encouraging trastuzumab-DM1 Phase II clinical findings presented
- New form of targeted therapy offers further hope to patients with advanced HER2-positive breast cancer
- New preliminary data from two studies show clinical activity of neratinib in combination with trastuzumab and in combination with paclitaxel in advanced HER2-positive breast cancer
- Data on more than 15 Novartis Oncology compounds highlight progress toward targeted therapies for diverse tumour types
Cervical Cancer
- Adding gemcitabine to chemoradiation improves survival but increases toxicity in patients with locally advanced cervical cancer
- Study showed Lilly's GEMZAR (gemcitabine HCl for injection) improved progression-free survival in cervical cancer patients
Ovarian Cancer
- Delayed symptom progression, better tolerability found with pegylated liposomal doxorubicin plus carboplatin for ovarian cancer
- Telik presents results from ASSIST-5 trial of Telcyta in platinum refractory and resistant ovarian cancer
- Sunesis Pharmaceuticals presents voreloxin clinical data
- OXiGENE reports positive data from Phase II trial of Zybrestat in platinum resistant ovarian cancer
- Boehringer Ingelheim presents new Phase II clinical data on two lead oncology compounds
Liver Cancer
- Data on more than 15 Novartis Oncology compounds highlight progress toward targeted therapies for diverse tumour types
Biliary-Tract Cancer
- Gemcitabine plus cisplatin reduces risks of death and progression in biliary-tract cancer
Stomach Cancer
- Cisplatin/S-1 noninferior to cisplatin/5-fluorouracil for advanced gastric cancer
- Trastuzumab plus chemotherapy improves survival in patients with human epidermal growth factor receptor 2-positive gastric cancer
- Herceptin extends overall survival by nearly three months in advanced stomach cancer
- Gastrointestinal Cancer
- Surgery following imatinib treatment appears to improve progression-free survival in patients with GIST
- Data on more than 15 Novartis Oncology compounds highlight progress toward targeted therapies for diverse tumour types
- Patients with GIST have increased risk of second, non-GIST malignancies
Oesophageal Cancer
- Paclitaxel poliglumex (Opaxio) added to cisplatin and radiation produces 45 percent pathologic complete remissions in patients with oesophageal cancer
Colorectal Cancer
- Curative surgery may be unnecessary for some patients with metastatic colorectal cancer
- Bayer Schering Pharma announces new data on novel anti-cancer compound BAY 73-4506
- Keryx Biopharmaceuticals announces positive data from a randomised, multi-centre, placebo-controlled, Phase II combination study of KRX-0401 (Perifosine) in the treatment of advanced metastatic colon cancer
- New gene assay predicts risk of colon cancer recurrence
- Oxaliplatin plus chemoradiation increases toxicity without affecting tumour response in patients with advanced rectal cancer
- Full data from failed study of Avastin in early-stage colon cancer released
- Poniard Pharmaceuticals announces progression-free survival data from Phase II clinical trial of picoplatin in metastatic colorectal cancer
Kidney Cancer
- Data on more than 15 Novartis Oncology compounds highlight progress toward targeted therapies for diverse tumour types
- Bayer Schering Pharma announces new data on novel anti-cancer compound BAY 73-4506
- GSK's pazopanib significantly delayed tumour progression in patients with advanced kidney cancer
- Pazopanib improves progression-free survival, response rate in patients with advanced renal cell carcinoma
- Antigenics presents positive Oncophage interim survival data
- ZymoGenetics reports encouraging Phase II results in renal cell cancer for IL-21 with Nexavar
- Keryx Biopharmaceuticals reports single agent Phase II data of KRX-0401 (perifosine) further demonstrating KRX-0401's activity in the treatment of advanced metastatic renal cell cancer
- AV-951 demonstrates prolonged progression-free survival and excellent safety profile in patients with advanced kidney cancer
- New Pfizer data helps to identify kidney cancer patients who may be most likely to benefit from treatment
Lung Cancer
- Oncothyreon announces clinical data from three product candidates presented
- Follow-up from Stimuvax study provides long-term safety data in advanced lung cancer patients receiving treatment for up to 8.2 years
- Data from Revlimid, Vidaza and amrubicin clinical trials reported in expanded haematology and oncology indications
- Peregrine Pharmaceuticals highlights promising early data from its three Phase II bavituximab cancer trials
- Vandetanib plus docetaxel combination prolongs progression-free survival in patients with non-small-cell lung cancer
- Vandetanib provides no additional progression-free survival benefit in patients with NSCLC compared with erlotinib
- AstraZeneca presents new late-stage Zactima data for lung cancer
- Mutation status appears to predict response to first-line gefitinib treatment for non-small-cell lung cancer
- Pemetrexed improves overall survival in patients with advanced non-small-cell lung cancer
- OSI reports Phase III results for Tarceva as first-line maintenance therapy for advanced NSCLC
- Maintenance with Avastin and Tarceva in combination helps lung cancer patients live longer without their disease worsening
- Erlotinib plus bevacizumab improves progression free survival in patients with NSCLC
- Boehringer Ingelheim presents new Phase II clinical data on two lead oncology compounds
- Gemin X announces positive results in small-cell lung cancer; 100 percent saw partial or complete response
- HRT may increase risk of lung cancer deaths in women with the disease
- Infinity reports encouraging clinical data for IPI-504
- Pfizer presents data with novel investigational agents in select patient groups with non-small-cell lung cancer
- Prophylactic cranial irradiation has no impact on overall survival in patients with NSCLC brain metastases
Malignant Mesothelioma
- Ranpirnase added to doxorubicin improves survival in pre-treated patients with malignant mesothelioma
Melanoma
- Data on more than 15 Novartis Oncology compounds highlight progress toward targeted therapies for diverse tumour types
- CuraGen updates CR011-vcMMAE data
- New data suggest treatment regimens that include Abraxane may be active in treating metastatic melanoma
- Genasense combined with Temodar and Abraxane shows preliminary evidence of high response rates and extended survival in patients with advanced melanoma
- Results from three Phase II studies reported a two-year survival rate ranging from 30 to 42 percent in metastatic melanoma patients treated with ipilimumab (10 mg/kg)
- Ipilimumab demonstrates favourable long-term survival rate in advanced melanoma
- Ipilimumab benefits patients with advanced melanoma regardless of immune-related adverse events
- Encouraging first data on new targeted treatment for patients with melanoma
- Novel vaccine doubles response in patients with metastatic melanoma
- Trial of elesclomol, paclitaxel in malignant melanoma stopped due to higher death rate
- BioVex to announce updated survival data from a Phase II clinical study of OncoVEX-CSF in metastatic melanoma
Uveal Melanoma
- Hana Biosciences presents updated Marqibo data
Pancreatic Cancer
- Similar benefits seen with gemcitabine, 5-fluorouracil/folinic acid in pancreatic cancer
- TNFerade Phase III data presented
- New data demonstrate anti-tumour activity for Abraxane combination chemotherapy regimen in patients with metastatic pancreatic cancer
Prostate Cancer
- Data from Revlimid, Vidaza and amrubicin clinical trials reported in expanded haematology and oncology indications
- Medivation announces positive new efficacy data from Phase I-II trial of MDV3100 in advanced prostate cancer patients
- New data from satraplatin Phase III trial in second-line castrate-refractory prostate cancer presented
- GTx's toremifene 80 mg increased bone mineral density in multiple clinically relevant subpopulations of prostate cancer patients on androgen deprivation therapy
- terna Zentaris presents data supporting evaluation of AEZS-108 in prostate cancer
- Cougar Biotechnology presents positive CB7630 (abiraterone acetate) Phase II data
- Prostvac data demonstrates the potential for significant increases in life expectancy in late-stage prostate cancer
- OncoGenex Pharmaceuticals announces OGX-011 treatment provides survival benefit in randomised Phase II trial in advanced metastatic prostate cancer
- Sprycel (dasatinib) shows potential as treatment for prostate cancer
- New Pfizer data helps to identify kidney cancer patients who may be most likely to benefit from treatment
- Oncolytics Biotech collaborators present positive Phase II sarcoma trial results
Multiple Cancers
- TransMolecular presents new data highlighting the anti-angiogenic and tumour-targeting properties of TM601
- Recurrent Glioblastoma
- Glioma/Melanoma/Lung Cancer/Colon Cancer/Pancreatic Cancer/Prostate Cancer/Breast Cancer/ Transitional cell carcinoma/pleomorphic xanthoastrocytoma/Metastatic paraganglioma
- Celldex Therapeutics announces CDX-1307 clinical data
- Colorectal/Pancreatic/Bladder/Ovarian/Breast cancers
- New clinical data for tesetaxel show anticancer activity and acceptable safety in ongoing study
- Nasopharyngeal/GIST/Uterine cancers
- Medarex announces efficacy data in cancer patients treated with investigational anti-PD-1 antibody
- Malignant Melanoma/Kidney/Colorectal/Lung/Prostate Cancers
- Oncothyreon announces clinical data from three product candidates presented
- Advanced Malignancy
- Advanced Cancer
- Isis highlights new clinical data on anti-cancer antisense drugs
- Prostate Cancer
- Prostate/Ovarian Cancers
- Acute Myeloid Leukaemia/Prostate Cancers
- OGX-427 treatment demonstrates safety, evidence of declines in circulating tumour cells and reductions in tumour markers in a Phase I cancer trial
- Breast/Ovarian/Prostate/Lung Cancers
- Antisoma's AS1409 shows anti-cancer activity in Phase I trial
- Multiple Melanoma/Multiple Cancers
- Exelixis reports encouraging Phase I data presented for XL228, a multi-targeted inhibitor of key cancer signalling kinases
- Lung/Pancreatic/Colorectal Cancers/Leiomyosarcoma
- EntreMed presents results of ENMD-2076 Phase I study in advanced cancer patients
- Melanoma, renal cell, ovarian and colorectal cancer
Solid Tumours
- Proteolix presents Phase Ib/II clinical data for carfilzomib in advanced solid tumour patients
- Exelixis reports encouraging Phase I data for XL765, a dual inhibitor of PI3K and mTOR
- Exelixis reports encouraging Phase I data for XL147, a selective inhibitor of PI3K
- Semafore's SF1126 is well tolerated and demonstrates activity in Phase I solid tumour patients
- Threshold Pharmaceuticals presents encouraging data from clinical trials of TH-302 for solid tumours
- Data on more than 15 Novartis Oncology compounds highlight progress toward targeted therapies for diverse tumour types
- 4SC presents Phase I data on its histone deacetylase (HDAC) inhibitor 4SC-201
- Enzon presents clinical data from HIF-1 alpha antagonist study
Leukaemia
- Acute Lymphoblastic Leukaemia
- Hana Biosciences presents updated Marqibo data
- Acute Myeloid Leukaemia/Myelodysplastic Syndromes
- Data from Revlimid, Vidaza and amrubicin clinical trials reported in expanded haematology and oncology indications
- Sunesis Pharmaceuticals presents voreloxin clinical data
- Cyclacel reports Phase II sapacitabine data in patients with acute myeloid leukaemia and myelodysplastic syndromes
- Antisoma to advance AS1411 in AML based on positive Phase II data
- Vion Pharmaceuticals presents data on Onrigin elderly AML trials
- Chronic Myeloid Leukaemia
- Once-Daily Dasatinib Remains Most Effective Dosing Schedule for Patients with Chronic Phase Chronic Myeloid Leukaemia
- ChemGenex says drug rids leukaemia from blood in 85 percent of patients
Lymphoma
- Hodgkin Lymphoma
- Xencor presents preliminary Phase I data on XmAb2513 antibody for lymphomas
- Seattle Genetics reports data from a weekly dosing Phase I clinical trial of SGN-35 in lymphoma
- SGN-35
- Dacetuzumab (SGN-40)
- Cytokinetics presents clinical data relating to SB-743921 in patients with non-Hodgkin or Hodgkin lymphoma
- Chronic Lymphocytic Leukaemia
- Immunomedics reports first efficacy results of subcutaneous humanised anti-CD20 antibody therapy of lymphoma with veltuzumab
- Trubion announces positive data from a Phase I/2 study of TRU-016 for the treatment of chronic lymphocytic leukaemia (CLL)
- Calistoga Pharmaceuticals' CAL-101 demonstrates clinical activity in haematologic cancers
- Large B-Cell Lymphoma
- In diffuse, large B-Cell non-Hodgkin lymphoma, R-CHOP14 is similar to R-CHOP21
- Final results with epratuzumab in combination with rituximab and chemotherapy in patients with aggressive lymphoma
- Follicular Lymphoma
- Positive, clinically significant Phase III results for personalised anti-cancer vaccine, BiovaxID presented
- Personalised Therapeutic Vaccine Prolongs Progression-Free Survival in Patients with Follicular Lymphoma
- The addition of Velcade (bortezomib) for injection to new and standard combinations delivers promising results in patients with non-Hodgkin lymphoma
- Mantle Cell Lymphoma
- Data from Revlimid, Vidaza and amrubicin clinical trials reported in expanded haematology and oncology indications
- T-cell Lymphoma
- Data from Revlimid, Vidaza and amrubicin clinical trials reported in expanded haematology and oncology indications
- Updated data from pivotal Phase II PROPEL study of pralatrexate
- Non-Hodgkin Lymphoma
- Pixantrone produces high rates of complete and partial remissions even among aggressive NHL patients with extensive prior doxorubicin treatment or prior rituximab treatment
- Pixantrone significantly increases complete remissions, overall response rates, frequency of durable remissions and progression free survival in patients with relapsed and refractory aggressive non-Hodgkin lymphoma
- Final therapy and safety results from Phase I/II study of veltuzumab, a second-generation anti-CD20 humanised antibody, published
- Addition of Velcade (bortezomib) for injection to new and standard combinations delivers promising results in patients with non-Hodgkin lymphoma
- Cytokinetics presents clinical data relating to SB-743921 in patients with non-Hodgkin or Hodgkin lymphoma
- Data from Revlimid, Vidaza and amrubicin clinical trials reported in expanded haematology and oncology indications
- Ziopharm presents positive darinaparsin clinical data
- Immunomedics reports first efficacy results of subcutaneous humanised anti-CD20 antibody therapy of lymphoma with veltuzumab
Multiple Myeloma
- Data on more than 15 Novartis Oncology compounds highlight progress toward targeted therapies for diverse tumour types
- Data from Revlimid, Vidaza and amrubicin clinical trials reported in expanded haematology and oncology indications
- Adding thalidomide to bortezomib, melphalan, prednisone improves progression-free survival in elders with multiple myeloma
- Immunomedics reports updated results of milatuzumab in dose-escalation study for multiple myeloma